We serve Chemical Name:(S)-b-aminoisobutyric acid CAS:4249-19-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(S)-b-aminoisobutyric acid
CAS.NO:4249-19-8
Synonyms:Propanoic acid, 3-amino-2-methyl-, (2S)-;(S)-3-aminoisobutyric acid zwitterion;(2S)-3-Amino-2-methylpropanoic acid
Molecular Formula:C4H9NO2
Molecular Weight:103.120
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:223.6±23.0 °C at 760 mmHg
Density:1.1±0.1 g/cm3
Index of Refraction:1.462
PSA:63.32000
Exact Mass:103.063332
LogP:-0.51
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Propanoic acid, 3-amino-2-methyl-, (2S)- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2S)-3-Amino-2-methylpropanoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(2S)-3-Amino-2-methylpropanoic acid Use and application,Propanoic acid, 3-amino-2-methyl-, (2S)- technical grade,usp/ep/jp grade.
Related News: We are pleased that intravenous rigosertib will be made compliantly available to suitable patients with higher-risk MDS through their physicians in designated countries. (S)-b-aminoisobutyric acid manufacturer Chung also said South Korean citizens who had visited the province in the past 14 days should voluntarily quarantine themselves at home for two weeks after they arrive back into the country. (S)-b-aminoisobutyric acid supplier We are pleased that intravenous rigosertib will be made compliantly available to suitable patients with higher-risk MDS through their physicians in designated countries. (S)-b-aminoisobutyric acid vendor We are pleased that intravenous rigosertib will be made compliantly available to suitable patients with higher-risk MDS through their physicians in designated countries. (S)-b-aminoisobutyric acid factory The company-backed investigation was based on interviews with more than 100 people, the May 20 memo to Lilly employees said. However, the memo did not respond to all concerns employees raised in their April complaint, which Reuters reviewed.
